Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium

Clarence E. Ehrlich, Peter C M Young, Frederick Stehman, Gregory P. Sutton, William M. Alford

Research output: Contribution to journalArticle

171 Citations (Scopus)

Abstract

Progesterone receptor content was measured in tissue samples from 175 patients with endometrial adenocarcinoma by use of the dextran-charcoal method. The estradiol receptor content was determined in 138 of these samples. Ninety-two tumors (52.6%) tested positive for progesterone receptors (50 fmol/mg cytosol protein) and 111 (80.4%) tested positive for estradiol receptors (6 fmol/mg). Median follow-up was 27.3 months (range 1 to 152 months). Progesterone receptor status correlated significantly with grade, histology, adnexal spread, age, and recurrence rate in stage I cancer. There was no correlation between progesterone receptor status and clinical stage, myometrial invasion, peritoneal cytology, retroperitoneal lymph node involvement, or spread to the cervix. Estradiol receptor status correlated with adnexal spread and recurrence rate. Recurrence in patients with stage I disease was significantly more common if tumors were negative for progesterone receptor (16 of 43, 37.2%) than if they were positive (four of 57, 7%; p < 0.001). Recurrence was also more common if tumors were negative for estradiol receptor (seven of 17, 41.2%) than if they were positive (eight of 63, 12.7%; p = 0.02). In recurrent or advanced disease, response to progestin was independent of estradiol receptor content, but tumors positive for progesterone receptors responded significantly more often than those lacking progesterone receptors. Overall survival was superior for patients with progesterone receptor-positive tumors (p = 0.001). Although survival in clinical stages I and II was also superior in patients with lesions positive for progesterone receptors (p = 0.13), there was no statistical difference in survival between patients with progesterone receptor-positive or -negative cancers and surgical stages I and II disease (p = 0.12). Estradiol receptor status had no apparent correlation with survival.

Original languageEnglish
Pages (from-to)796-805
Number of pages10
JournalAmerican Journal of Obstetrics and Gynecology
Volume158
Issue number4
DOIs
StatePublished - 1988

Fingerprint

Steroid Receptors
Progesterone Receptors
Endometrium
Estradiol Receptors
Adenocarcinoma
Neoplasms
Recurrence
Survival
Charcoal
Progestins
Dextrans
Cervix Uteri
Cytosol
Cell Biology
Histology
Lymph Nodes

Keywords

  • endometrial cancer
  • progestin therapy
  • prognosis
  • Steroid receptors

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. / Ehrlich, Clarence E.; Young, Peter C M; Stehman, Frederick; Sutton, Gregory P.; Alford, William M.

In: American Journal of Obstetrics and Gynecology, Vol. 158, No. 4, 1988, p. 796-805.

Research output: Contribution to journalArticle

Ehrlich, Clarence E. ; Young, Peter C M ; Stehman, Frederick ; Sutton, Gregory P. ; Alford, William M. / Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. In: American Journal of Obstetrics and Gynecology. 1988 ; Vol. 158, No. 4. pp. 796-805.
@article{a0629ef14a6c4f0fb45cfdc353743117,
title = "Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium",
abstract = "Progesterone receptor content was measured in tissue samples from 175 patients with endometrial adenocarcinoma by use of the dextran-charcoal method. The estradiol receptor content was determined in 138 of these samples. Ninety-two tumors (52.6{\%}) tested positive for progesterone receptors (50 fmol/mg cytosol protein) and 111 (80.4{\%}) tested positive for estradiol receptors (6 fmol/mg). Median follow-up was 27.3 months (range 1 to 152 months). Progesterone receptor status correlated significantly with grade, histology, adnexal spread, age, and recurrence rate in stage I cancer. There was no correlation between progesterone receptor status and clinical stage, myometrial invasion, peritoneal cytology, retroperitoneal lymph node involvement, or spread to the cervix. Estradiol receptor status correlated with adnexal spread and recurrence rate. Recurrence in patients with stage I disease was significantly more common if tumors were negative for progesterone receptor (16 of 43, 37.2{\%}) than if they were positive (four of 57, 7{\%}; p < 0.001). Recurrence was also more common if tumors were negative for estradiol receptor (seven of 17, 41.2{\%}) than if they were positive (eight of 63, 12.7{\%}; p = 0.02). In recurrent or advanced disease, response to progestin was independent of estradiol receptor content, but tumors positive for progesterone receptors responded significantly more often than those lacking progesterone receptors. Overall survival was superior for patients with progesterone receptor-positive tumors (p = 0.001). Although survival in clinical stages I and II was also superior in patients with lesions positive for progesterone receptors (p = 0.13), there was no statistical difference in survival between patients with progesterone receptor-positive or -negative cancers and surgical stages I and II disease (p = 0.12). Estradiol receptor status had no apparent correlation with survival.",
keywords = "endometrial cancer, progestin therapy, prognosis, Steroid receptors",
author = "Ehrlich, {Clarence E.} and Young, {Peter C M} and Frederick Stehman and Sutton, {Gregory P.} and Alford, {William M.}",
year = "1988",
doi = "10.1016/0002-9378(88)90075-0",
language = "English",
volume = "158",
pages = "796--805",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium

AU - Ehrlich, Clarence E.

AU - Young, Peter C M

AU - Stehman, Frederick

AU - Sutton, Gregory P.

AU - Alford, William M.

PY - 1988

Y1 - 1988

N2 - Progesterone receptor content was measured in tissue samples from 175 patients with endometrial adenocarcinoma by use of the dextran-charcoal method. The estradiol receptor content was determined in 138 of these samples. Ninety-two tumors (52.6%) tested positive for progesterone receptors (50 fmol/mg cytosol protein) and 111 (80.4%) tested positive for estradiol receptors (6 fmol/mg). Median follow-up was 27.3 months (range 1 to 152 months). Progesterone receptor status correlated significantly with grade, histology, adnexal spread, age, and recurrence rate in stage I cancer. There was no correlation between progesterone receptor status and clinical stage, myometrial invasion, peritoneal cytology, retroperitoneal lymph node involvement, or spread to the cervix. Estradiol receptor status correlated with adnexal spread and recurrence rate. Recurrence in patients with stage I disease was significantly more common if tumors were negative for progesterone receptor (16 of 43, 37.2%) than if they were positive (four of 57, 7%; p < 0.001). Recurrence was also more common if tumors were negative for estradiol receptor (seven of 17, 41.2%) than if they were positive (eight of 63, 12.7%; p = 0.02). In recurrent or advanced disease, response to progestin was independent of estradiol receptor content, but tumors positive for progesterone receptors responded significantly more often than those lacking progesterone receptors. Overall survival was superior for patients with progesterone receptor-positive tumors (p = 0.001). Although survival in clinical stages I and II was also superior in patients with lesions positive for progesterone receptors (p = 0.13), there was no statistical difference in survival between patients with progesterone receptor-positive or -negative cancers and surgical stages I and II disease (p = 0.12). Estradiol receptor status had no apparent correlation with survival.

AB - Progesterone receptor content was measured in tissue samples from 175 patients with endometrial adenocarcinoma by use of the dextran-charcoal method. The estradiol receptor content was determined in 138 of these samples. Ninety-two tumors (52.6%) tested positive for progesterone receptors (50 fmol/mg cytosol protein) and 111 (80.4%) tested positive for estradiol receptors (6 fmol/mg). Median follow-up was 27.3 months (range 1 to 152 months). Progesterone receptor status correlated significantly with grade, histology, adnexal spread, age, and recurrence rate in stage I cancer. There was no correlation between progesterone receptor status and clinical stage, myometrial invasion, peritoneal cytology, retroperitoneal lymph node involvement, or spread to the cervix. Estradiol receptor status correlated with adnexal spread and recurrence rate. Recurrence in patients with stage I disease was significantly more common if tumors were negative for progesterone receptor (16 of 43, 37.2%) than if they were positive (four of 57, 7%; p < 0.001). Recurrence was also more common if tumors were negative for estradiol receptor (seven of 17, 41.2%) than if they were positive (eight of 63, 12.7%; p = 0.02). In recurrent or advanced disease, response to progestin was independent of estradiol receptor content, but tumors positive for progesterone receptors responded significantly more often than those lacking progesterone receptors. Overall survival was superior for patients with progesterone receptor-positive tumors (p = 0.001). Although survival in clinical stages I and II was also superior in patients with lesions positive for progesterone receptors (p = 0.13), there was no statistical difference in survival between patients with progesterone receptor-positive or -negative cancers and surgical stages I and II disease (p = 0.12). Estradiol receptor status had no apparent correlation with survival.

KW - endometrial cancer

KW - progestin therapy

KW - prognosis

KW - Steroid receptors

UR - http://www.scopus.com/inward/record.url?scp=0023932927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023932927&partnerID=8YFLogxK

U2 - 10.1016/0002-9378(88)90075-0

DO - 10.1016/0002-9378(88)90075-0

M3 - Article

C2 - 2966586

AN - SCOPUS:0023932927

VL - 158

SP - 796

EP - 805

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 4

ER -